Chordia Therapeutics (TSE:190A) OCF Yield %: -23.03 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
11 GF Score
Price 円77.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics OCF Yield %?

Chordia Therapeutics TSE:190A -2.53% 11 OCF Yield % is -23.03 as of Jul. 21, 2026. GuruFocus rates TSE:190A with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, Chordia Therapeutics ranks worse than 70% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Chordia Therapeutics's Trailing 12-Month Cash Flow from Operations is 円-1,333.59 Mil, and Market Cap is 円5,791.66 Mil. Therefore, Chordia Therapeutics's OCF Yield % for today is -23.03%.

The historical rank and industry rank for Chordia Therapeutics's OCF Yield % or its related term are showing as below:

TSE:190A' s OCF Yield % Range Over the Past 10 Years
Min: -23.03   Med: 4.84   Max: 14.38
Current: -23.03


During the past 5 years, the highest OCF Yield % of Chordia Therapeutics was 14.38%. The lowest was -23.03%. And the median was 4.84%.

TSE:190A's OCF Yield % is ranked worse than
70% of 1410 companies
in the Biotechnology industry
Industry Median: -8.565 vs TSE:190A: -23.03

Chordia Therapeutics's OCF Margin % for the quarter that ended in Feb. 2026 was %.


Chordia Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Chordia Therapeutics OCF Yield % Related Terms


Chordia Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics OCF Yield % Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
OCF Yield %
0.00 0.00 0.00 -3.67 -14.79

Chordia Therapeutics Semi-Annual Data
Aug21 Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
OCF Yield % Get a 7-Day Free Trial 0.00 -3.35 -13.24 -11.64 -9.93

TSE:190A vs VRTX, REGN, ALNY: OCF Yield % Comparison

For the Biotechnology subindustry, Chordia Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordia Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Chordia Therapeutics's OCF Yield % falls into.


TSE:190A
11GF Score
Chordia Therapeutics Inc TSE:190A
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Chordia Therapeutics's OCF Yield % for the fiscal year that ended in Aug. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-1836.921 / 12418.02
=-14.79%

Chordia Therapeutics's annualized OCF Yield % for the quarter that ended in Feb. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-611.138 * 2 / 12313.077
=-9.93%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -23.03 mean?
Chordia Therapeutics (TSE:190A) has a OCF Yield % of -23.03 as of Jul. 21, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Chordia Therapeutics and its competitors. According to the industry distribution chart, Chordia Therapeutics ranks #987 out of 1410 companies in the Biotechnology industry, placing it in the top 70%.
Is Chordia Therapeutics' OCF Yield % too high?
Chordia Therapeutics' current OCF Yield % is -23.03. Based on the distribution chart, Chordia Therapeutics ranks #987 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chordia Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chordia Therapeutics ranks #987 out of 1410 companies for OCF Yield %. This places Chordia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Chordia Therapeutics and its competitors. Chordia Therapeutics's current OCF Yield % is -23.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current OCF Yield % of -23.03. The current OCF Yield % is -23.03. Chordia Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current OCF Yield % is -23.03 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
11GF Score

Get the complete analysis for TSE:190A

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円77.00
Price